<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01897610</url>
  </required_header>
  <id_info>
    <org_study_id>ILC-IIT-04</org_study_id>
    <nct_id>NCT01897610</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC</brief_title>
  <official_title>Randomized, Open-label and Multi-center Clinical Trial to Evaluate the Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Cell Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Cell Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;Immuncell-LC&quot; in aspects of therapeutic efficacy and safety when administered with Nexavar
      to advanced Hepatocellular carcinoma patients when compared with the control group who did
      not receive administration of the drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  primary outcome Compare clinical efficacy of group treated with cell therapeutic
           Immuncell-LC evaluated by progression free survival with that of untreated group

        -  secondary outcome compare clinical efficacy of group treated with Immuncell-LC, a drug
           for treating advanced hepatocellular carcinoma evaluated by overall survival, disease
           control rate, changes of Alpha Feto Protein(AFP) figures from baseline to the last
           observation date and that of untreated group and evaluate adverse reactions, clinical
           pathological tests and its safety.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">July 4, 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess progression-free survival (PFS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>CT, PET-CT, MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the overall survival (OS)</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Disease control rate</measure>
    <time_frame>up to 2 years</time_frame>
    <description>to determine response rate (CR, PR, SD rate) from the baseline to the late observation date using mRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the changes of Alpha Feto Protein(AFP)figures from baseline to the last observation date</measure>
    <time_frame>up to 2 years</time_frame>
    <description>analysing the changes of AFP before and after combination Nexavar plus Immuncell-LC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The study subjects randomly assigned to the control group is given Nexavar chemotherapy according to the clinical test plans.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immuncell-LC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study subjects assigned to the test group blood is drawn before minimum 2 weeks in order to manufacture the test drug. Test group is compared its progression free survival rate after baseline by administering Nexavar chemotherapy same as control group with Immuncell-LC (10 times).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immuncell-LC</intervention_name>
    <description>intravenous dripping of 200ml(10^9~2x10^10 lymphocytes/60kg adult) for 1 hour</description>
    <arm_group_label>Immuncell-LC group</arm_group_label>
    <other_name>Activated T lymphocyte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have consented to the study by providing signature of self, guardian or
             legal representative

          -  The patient is more than 20 and less than 80 years old

          -  The patient is diagnosed as hepatocellular carcinoma by pathological/radiological test
             and in the stage of III or IV

          -  Child-Pugh Score should be A

          -  ECOG Performance Status (ECOG-PS) is less than 2 or equal to

          -  Patients who receiving or ready for Nexavar treatment

          -  Patients who satisfy the following conditions of the blood test and kidney function
             test

               -  Absolute granulocyte count is bigger than 1,000/µL

               -  Hemoglobin is bigger than 8.5 g/dL

               -  Platelet count is bigger than 5x10^10/L

               -  Blood Urea Nitrogen(BUN) or Creatinine 1.5xupper normal limit

        Exclusion Criteria:

          -  Patients who are immune deficient or have a history of auto-immune diseases (Ex.
             Rheumatoid Arthritism, Systemic Lupus Erythematosus, Vasculitis, Multiple sclerosis,
             Adolescent Insulin-Dependent Diabetes Mellitus, etc.)

          -  Patients who have a history of malignant tumors in the recent 5 years prior to the
             study with the exception of basal cell carcinoma, local prostate cancer, and cervical
             cancer, liver cancer.

          -  Patients who had anti-cancer medication before the study with the exception of Nexavar

          -  Patients who has serious dysfunction in other organs by sub-investigator's opinion

          -  Patients has serious allergic-history by sub-investigator's opinion

          -  Patients has serious mental disease sub-investigator's opinion

          -  Pregnant women, nursing mother of having intention of being pregnant during the study

          -  Patients who participated in other clinical trial within 4 weeks before this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soon Ho Um, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-750</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul ST. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Di Maio M, De Maio E, Perrone F, Pignata S, Daniele B. Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S109-14. Review.</citation>
    <PMID>12394214</PMID>
  </reference>
  <reference>
    <citation>Ganne-Carrié N, Trinchet JC. Systemic treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2004 Mar;16(3):275-81. Review.</citation>
    <PMID>15195890</PMID>
  </reference>
  <reference>
    <citation>Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.</citation>
    <PMID>19095497</PMID>
  </reference>
  <reference>
    <citation>Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.</citation>
    <PMID>18650514</PMID>
  </reference>
  <reference>
    <citation>Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 2008 Jan;99(1):159-65. Epub 2007 Oct 22.</citation>
    <PMID>17953709</PMID>
  </reference>
  <reference>
    <citation>Shim JH, Park JW, Choi JI, Park BJ, Kim CM. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. J Cancer Res Clin Oncol. 2009 Apr;135(4):617-25. doi: 10.1007/s00432-008-0496-x. Epub 2008 Oct 10.</citation>
    <PMID>18846384</PMID>
  </reference>
  <reference>
    <citation>Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000 Sep 2;356(9232):802-7. Erratum in: Lancet 2000 Nov 11;356(9242):1690.</citation>
    <PMID>11022927</PMID>
  </reference>
  <reference>
    <citation>Kim HM, Lim J, Yoon YD, Ahn JM, Kang JS, Lee K, Park SK, Jeong YJ, Kim JM, Han G, Yang KH, Kim YJ, Kim Y, Han SB. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Int Immunopharmacol. 2007 Dec 15;7(13):1793-801. Epub 2007 Aug 31.</citation>
    <PMID>17996690</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2013</study_first_submitted>
  <study_first_submitted_qc>July 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immuncell-LC, advanced hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

